The use of oral tenofovir disoproxil fumarate combined with emtricitabine as preexposure prophylaxis (PrEP) effectively protects men who have sex with men (MSM) against human immunodeficiency virus (HIV) infection.^[@bib1]^ Both daily and event-driven PrEP are highly effective.^[@bib1],[@bib2]^ Adherence is the strongest determinant of effectiveness.^[@bib1]^ For daily PrEP, pill counts and drug level measurements are used to measure adherence, but event-driven use requires more advanced monitoring addressing correspondence of PrEP use and sexual activity.

The collection of data using electronic tools is an accepted strategy in many areas of health research and is reported to improve speed and scalability of data collection while reducing costs.^[@bib3]^ Computer-based technology may be an acceptable and effective way to deliver HIV (prevention) interventions^[@bib4],[@bib5]^ and support adherence.^[@bib6]^ Several commercially available mobile applications (apps) allow tracking of sexual activity.^[@bib7]^ However, studies on the feasibility of collecting data on sexual behavior and PrEP adherence via an app are lacking, and the validity of those data has not been established. The aim of this study was to investigate the use of an app to gather data on PrEP adherence and sexual risk behavior, to determine factors associated with reporting data in the app, and to compare sexual behavior and PrEP adherence data collected with this app with data from questionnaires.

MATERIALS AND METHODS
=====================

Study Design Amsterdam PrEP Project
-----------------------------------

The Amsterdam PrEP project (AMPrEP) is an open-label demonstration project conducted by the Public Health Service of Amsterdam which investigates the uptake, acceptability and feasibility of PrEP for HIV prevention, including adherence and sexual behavior. Study procedures were published previously.^[@bib8]^ In short, enrolment took place at the Public Health Service of Amsterdam between August 17, 2015, and June 24, 2016. Men who have sex with men and transgender people were eligible if they were at least 18 years old, HIV negative, at higher risk of acquiring HIV, and had no contraindications for PrEP. Participants made a choice between daily (one pill every day) or event-driven PrEP (2 pills between 24 and 2 hours before, and 1 pill every 24 hours until 48 hours after the last sexual encounter). Switching was allowed at each study visit. At 3-months study visits, participants completed a questionnaire.

Informed consent was obtained from all participants. Ethical approval for AMPrEP was obtained from the Medical Research Ethics Committee of the Amsterdam Medical Center (NL49504.018.14). The study protocol is registered at the Dutch Trial Register.^[@bib9]^

Measurement Instruments
-----------------------

### The AMPrEP App

The app was developed as a tool to collect health information and as a reminder service to take PrEP for participants of the AMPrEP project. The app was designed for Android and iOS. At the PrEP initiation visit, participants were requested to daily report PrEP intake and sexual behavior in the app during study participation. Access to the app was restricted to study participants through the use of a personal registration code and data were saved at a protected server of our institution using a unique study identifier. Each participant was asked to complete 2 to 8 daily questions: (1) "Did you take the pill today?", to be answered by "yes" or "no"; and: (2) "Did you have anal sex today?", to be answered by "yes" or "no"; and if "yes": (3) "With an unknown partner?"; (4) "With a known partner?"; and (5) "With a steady partner?", each to be answered by "yes" or "no." If "yes" to questions 3, 4 or 5, the number of partners and condom use per category was asked.

A randomized controlled trial (RCT) on adherence support for daily PrEP users through an extended version of the app, is embedded in the AMPrEP project and is registered in the Dutch Trial Register, number NTR5741. The extended app provided a visualization of self-reported pill use and sexual activity because use of the app Interfaces of the standard and the extended app are shown in Supplementary Figures 1 and 2, <http://links.lww.com/OLQ/A367>, <http://links.lww.com/OLQ/A368>.

### Three Monthly Questionnaires

Participants completed a self-administered computer-assisted questionnaires about sexual risk behavior and adherence every 3 months, which contained questions on the same topics as the app but formulated differently. Questions pertinent to this analysis were: "How many pills did you take in the past 30 days?" and "How many unknown casual partners have you had anal sex with in the past 3 months?"

Outcomes
--------

### Baseline Characteristics

Characteristics that were recorded were: chosen PrEP strategy, age, ethnicity, residence, sexual preference, educational level, employment, monthly net income, current steady relationship, living situation, sexual risk behavior, alcohol use and drug use. To assess presence of alcohol and drug use disorders, the Alcohol Use Disorders Identification Test (AUDIT)^[@bib10]^ and Drug Use Disorders Identification Test (DUDIT)^[@bib11]^ were used. The AUDIT and DUDIT are validated questionnaires with, respectively, 10 and 11 items and with resulting scores ranging from 0 to 40 and from 0 to 44. An AUDIT score of 8 or more suggests harmful alcohol use. A DUDIT score of 8 or more suggests harmful drug use.

### Use of the App Over Time

Data of the first 12 study months of participation were used. Days in the dataset were converted into 30-day periods ("study months"). The first study month started at the PrEP initiation visit.

Using the app was defined as reporting data on at least 1 record (day). The proportion of participants who reported data into the app over time was calculated per study month. The proportions were categorized as 0 days (0%), 1 to 14 days (\>0% to \< 50%), 15 to 26 days (≥50% to \< 90%), and 27 to 30 days (≥90%) per study month.

### Sexual Behavior and PrEP Adherence

To compare questionnaire and app data, we assessed the reported number of unknown casual partners. Regarding adherence, participants could indicate whether they had taken a pill on a particular day, but not the number of pills. In the analysis, we assumed 2 pills were taken whenever an event-driven PrEP user started a PrEP course. Inadvertently, pills taken reported in the questionnaire at the 12-month visit for daily PrEP users were not registered.

Statistical Analysis
--------------------

Transgender people were excluded from analysis because numbers were small (n = 2). Baseline characteristics are presented as means and standard deviation for normally distributed continuous data and total number with percentage for categorical data. Differences in baseline characteristics between daily and event-driven PrEP users were compared with 2-sided *t* tests and χ^2^ tests.

The first time participants stopped reporting data in the app for a prolonged period of time was analyzed with a Kaplan-Meier curve. Time was presented as study months and an event was defined as not reporting data in the app during at least 30 consecutive days.

To determine factors associated with reporting data on a given day in the app, Poisson regression using generalized estimating equations was done, because each participant provided multiple data points (up to 360 days), resulting in a ratio of count means. Factors associated with a *P* value of \<0.2 in univariable regression were included in multivariable analysis; a stepwise backward procedure was used to select significant determinants of daily reporting in the app. For participants who switched PrEP strategy, the strategy used at the day of reporting data in the app was used for Poisson regression. For this analysis, data from those randomized to the intervention arm of the adherence support RCT were censored at enrolment in the RCT.

We conducted a negative binomial regression to determine characteristics associated with being a consistent app user. Participants who completed ≥90% of the days in each month for the first 6 study months were defined as consistent app users. Factors associated at *P* \< 0.2 in univariable regression were included in multivariable analysis; through a stepwise backward procedure we obtained a parsimonious model with adjusted prevalence ratios.

Wilcoxon signed-rank tests were used to compare the distributions of the number of pills taken and of casual sexual partners among consistent app users, gathered through app or questionnaire. Wilcoxon rank-sum tests were used to compare the distributions of the number of pills taken according to the questionnaire between consistent and inconsistent app users. Consistent app users reported data in the app ≥90% of the days preceding the questionnaire (ie, ≥27 days for pill count and ≥81 days for sexual partner count).

Data collected from PrEP initiation until November 28, 2017, were used. Analyses were done with STATA 13.1 (STATA Corporation, College Station, TX).^[@bib12]^ The significance threshold was set at *P* less than 0.05.

RESULTS
=======

Study Population
----------------

All 374 MSM participating in the AMPrEP project were included in this analysis. Three hundred fifty-six (92.5%) of these completed 12 months of follow-up; 18 (7.5%) had stopped participation or were lost-to-follow-up. Baseline characteristics of the full cohort were published previously^[@bib8]^; characteristics of the population used for this study are presented in Supplementary Table 1, <http://links.lww.com/OLQ/A369>. Mean age was 40.6 years (standard deviation \[SD\], 11.6). Most participants were white (85.1%) and living in Amsterdam (61.2%). The majority was highly educated (76.6%) and employed (78.4%). Over one third (40.4%) had a monthly net income between €1701 and €2950. At PrEP initiation, 272 participants opted for daily and 102 participants for event-driven PrEP. Daily PrEP users were significantly younger than event-driven PrEP users (mean age, 39.2 vs. 44.2). Compared with event-driven PrEP users, daily users were less likely to be employed and more likely to be a student; a smaller proportion of daily users lived alone and a larger proportion lived together with other people.

AMPrEP App Use Over Time
------------------------

Figure [1](#F1){ref-type="fig"} shows the proportions of days on which data were reported in the app per study month. The percentage of participants reporting data for 27 to 30 days (≥90%) per study month decreased over time (*P* \< 0.001). The percentage of participants reporting data for zero days per study month increased. However, over 60% of the participants reported data in the app for 27 to 30 days (≥90%) in the twelfth study month.

![AMPrEP app use over time among MSM participating in AMPrEP, Amsterdam, 2015--2017: the proportions of days on which data were reported in the app, per study month.](olq-46-400-g001){#F1}

A Kaplan-Meier curve of app use over time is depicted in Figure [2](#F2){ref-type="fig"}. All participants (n = 374) were at risk of not reporting data in the app for 30 consecutive days. In total 10.2% of participants did not use the app in their first month in AMPrEP. The use of the app decreased gradually during time spent in the study. After 12 months, 37.7% had a 30-day period of non--app use.

![Kaplan-Meier curve of time to 30 consecutive days of non-use of app among MSM participating in AMPrEP, Amsterdam, 2015--2017.](olq-46-400-g002){#F2}

Characteristics Associated With Reporting Data in the AMPrEP App
----------------------------------------------------------------

Table [1](#T1){ref-type="table"} shows the variables associated with reporting data in the app. In univariable analysis, earlier study month, higher income, with a possible threshold effect at 1700 euro, and potentially harmful drug use were significantly associated with reporting data in the app on a given day.

###### 

Univariable and Multivariable Poisson Regression Analyses Using GEE to Determine Factors Associated With Reporting Data per Day in the App for MSM Participating in AMPrEP, Amsterdam 2015--2017

![](olq-46-400-g003)

In multivariable analysis, earlier study month and event-driven PrEP strategy were significantly associated with less frequent reporting of data in the app (adjusted ratio \[aR\] of count means, 0.98 \[95% confidence interval (CI), 0.97--0.99\] per additional month and aR for using daily PrEP aR 0.86 \[95% CI, 0.74--1.00\]).

In sensitivity analysis, using daily PrEP and having a middle or high income were significantly associated with being a consistent app user (Supplementary Table 2, <http://links.lww.com/OLQ/A370>).

Comparison of App Data to Questionnaire Data
--------------------------------------------

In the daily PrEP group, PrEP adherence by app data and questionnaire data was comparable: the median of the monthly number of pills taken was 30 at 3, 6, and 9 months (Table [2](#T2){ref-type="table"}). Among event-driven PrEP users, the median number of pills taken according to the app tended to be lower than the number reported in the questionnaire; this difference was only significant in the ninth month (*P* = 0.009).

###### 

Comparison of Self-Reported Number of Pills Taken and Self-Reported Number of Unknown Casual Partners by MSM With Recent Consistent App-Use in AMPrEP, Between App and Questionnaire, Amsterdam 2015--2017

![](olq-46-400-g004)

Sensitivity analysis showed that the reported number of pills taken (questionnaire) was similar for consistent and inconsistent app users; nevertheless the difference was significant among daily users (Supplementary Tables 3 and 4, <http://links.lww.com/OLQ/A371>).

The number of unknown casual partners reported by both daily and event-driven PrEP users was comparable between the app and questionnaire assessment, with the exception of the twelfth month among event-driven PrEP users, where the number reported in the app was significantly higher (*P* = 0.016).

DISCUSSION
==========

In this study among MSM in the Netherlands, the use of an app to collect daily data on adherence of PrEP and sexual behavior among MSM was high in the first year. Factors associated with reporting data in the app were study month and having chosen a daily PrEP strategy. Among those who reported recent data in the app, app data on pill intake and number of unknown casual sex partners were comparable to data collected with questionnaires.

We observed a decrease in the number of days that participants contributed data to the app over time. In the first study month, approximately 75% of study participants reported data in the app on 90% or greater of days; this decreased to 62% in the 12th month. This decrease over time is in line with other studies that investigated the use of apps to improve health containing daily diaries.^[@bib13],[@bib14]^ Similarly, we found an association of being in the study for a shorter period of time with reporting data in the app. In addition, daily PrEP was associated with completing daily app data. These factors are non-modifiable and thus should be accounted for when designing an intervention, for example, regular addition of new features to a daily data collection app.

Adherence data collected with the app were similar to those collected with questionnaires for daily and event-driven PrEP users for those using the app consistently. However, in the ninth month the data were variant for event-driven PrEP users. There are 3 possible explanations. First, when adherence among daily users is maximal, 30 pills taken in 30 days, this is relatively easy to remember. For event-driven use, it may be harder to remember how many pills were taken, and hence a small variation between daily and quarterly data collection may have occurred. Second, participants who chose a daily strategy may be different from event-driven users in a way that causes them to be more consistent in data reporting. In the IPERGAY study,^[@bib2]^ where adherence was measured through pill counts, event-driven PrEP users took a median number of 15 pills per month, which was comparable to their questionnaire data. Measurement of adherence to PrEP is challenging, especially for event-driven PrEP use. No gold standard exists and it is difficult to assess which method best approximates the truth.^[@bib15]^ An additional benefit of daily data collection is that PrEP coverage of sex acts can be assessed. Third, this could be caused by a type 1 error, due to the number of comparisons being made. However, observed changes between app and questionnaire data were small, indicating that app data collection on pill use may replace questionnaire data collection.

Regarding sexual behavior, a gold standard for data collection is not available. We showed that data on sexual behavior collected daily via an app were comparable to aggregated quarterly data collected by questionnaire among consistent app users. This is reassuring in 2 ways: it suggests apps may be used for daily data collection on sexual behavior, and that app-based data collection is reliable, as it is comparable to the most common way of eliciting sexual behavior data, by questionnaires.

Strengths
---------

This study has several strengths. This is the first study describing the use of an app to collect data related to PrEP adherence and sexual behavior over time. We showed reliability of data when collected daily via an app as compared to questionnaire data collected every 3 months. As e-health technology is only just starting to take off and many health apps may be developed in the coming years,^[@bib16]^ this proof of feasibility of an app to collect reliable adherence and sexual behavior data is very helpful for researchers and mobile technology developers.

Furthermore, we collected data on PrEP adherence related to sexual exposure, which may allow for accurate assessment of coverage of sex acts and accurate adherence. Event-driven PrEP is not used widely, although a varying proportion of PrEP users is interested in this regimen in several settings.^[@bib2],[@bib8]^ Information on how event-driven PrEP is used is needed. Because individualized prevention is preferable over a blanket strategy, data from this study may aid to effectively inform and support those who want to use PrEP, resulting in optimal HIV transmission prevention.

Limitations
-----------

This study has several limitations. First, highly educated people were over-represented in our study and this group may adopt innovative health technology more easily than those with less education.^[@bib17],[@bib18]^ Transgender people were excluded as their number was too small to derive meaningful conclusions. Whether an app designed to collect data on adherence and sexual behavior will be used by the wider MSM and transgender community needs to be investigated in future PrEP roll-out studies.

Second, for the comparison of app data to questionnaire data, only participants were included who reported data in the app 90% or greater of the 30 days before the questionnaire for pill count and 90% or greater of the 90 days before the questionnaire for unknown casual partners. The conclusion of comparability between app data and questionnaire data may thus only apply to participants who provided data in the app on 90% or greater of days. More data are also needed on app use in event-driven PrEP users, because sample size in this study was relatively small. Additionally, the app did not track the number of doses of PrEP event-driven PrEP users took.

Third, we did not investigate the reasons for not entering data in the app; qualitative research may guide designing interventions for app engagement in the long haul.

A final limitation is that participants may have used the app when completing the standard questionnaire to help them remember the number of pills they took and casual partners they had.

The AMPrEP app can successfully monitor PrEP adherence and collect data on sexual behavior. App use was high with a decrease over time. The majority of the data collected with the app were similar to questionnaire data among those using the app consistently. The use of an app aimed at collecting research data and reminding people to use PrEP is a very promising tool to assist men in being adherent and to collect detailed data on sensitive topics.
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